{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:32:37Z","timestamp":1792096357921,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,15]]},"DOI":"10.2146\/ajhp170399","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T06:25:19Z","timestamp":1528352719000},"page":"861-869","source":"Crossref","is-referenced-by-count":10,"title":["Herpes zoster subunit vaccine for the prevention of herpes zoster"],"prefix":"10.1093","volume":"75","author":[{"given":"Melanie R.","family":"Symoniak","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY"},{"name":"Department of Pharmacy, Rochester General Hospital, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Farrokh","sequence":"additional","affiliation":[{"name":"Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judianne C.","family":"Slish","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY"},{"name":"Department of Pharmacy, UR Medicine Highland Hospital, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041604203870700_b1-0750861","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"2019041604203870700_b2-0750861","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2019041604203870700_b3-0750861","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/651078","article-title":"Increasing incidence of herpes zoster among veterans","volume":"50","author":"Rimland","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019041604203870700_b4-0750861","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2019041604203870700_b5-0750861","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"2019041604203870700_b6-0750861","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archinte.1982.00340150091017","article-title":"Immune responses to varicella-zoster in the aged","volume":"142","author":"Burke","year":"1982","journal-title":"Arch Intern Med"},{"key":"2019041604203870700_b7-0750861","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"key":"2019041604203870700_b8-0750861","article-title":"Zostavax (zoster vaccine live) prescribing information","author":"Merck & Co., Inc"},{"key":"2019041604203870700_b9-0750861","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019041604203870700_b10-0750861","article-title":"May 25, 2006 approval letter\u2014Zostavax","author":"Food and Drug Administration"},{"key":"2019041604203870700_b11-0750861","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2019041604203870700_b12-0750861","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019041604203870700_b13-0750861","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019041604203870700_b14-0750861","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u2265 60 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"2019041604203870700_b15-0750861","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"key":"2019041604203870700_b16-0750861","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2019041604203870700_b17-0750861","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2019041604203870700_b18-0750861","article-title":"GSK announces US regulatory submission of candidate vaccine for prevention of shingles","author":"GlaxoSmithKline","year":"2016"},{"key":"2019041604203870700_b19-0750861","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"2019041604203870700_b20-0750861","article-title":"Shingrix (zoster vaccine recombinant, adjuvanted) prescribing information","author":"GlaxoSmithKline"},{"key":"2019041604203870700_b21-0750861","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.mi.44.100190.000423","article-title":"Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking","volume":"44","author":"Grose","year":"1990","journal-title":"Annu Rev Microbiol"},{"key":"2019041604203870700_b22-0750861","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults \u2265 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label trial","volume":"13","author":"Godeaux","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2019041604203870700_b23-0750861","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/infdis\/jix482","article-title":"Immunogenicity and safety of the HZ\/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live-attenuated herpes zoster vaccine","volume":"216","author":"Grupping","year":"2017","journal-title":"J Infect Dis"},{"key":"2019041604203870700_b24-0750861","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"2019041604203870700_b25-0750861","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"2019041604203870700_b26-0750861","article-title":"GSK announces EU regulatory submission of candidate vaccine for prevention of shingles\u2014follows regulatory submissions in US and Canada","author":"GlaxoSmithKline","year":"2016"},{"key":"2019041604203870700_b27-0750861","article-title":"GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles","author":"GlaxoSmithKline","year":"2017"},{"key":"2019041604203870700_b28-0750861","article-title":"GSK announces first approval of Shingrix in Canada","author":"GlaxoSmithKline","year":"2017"},{"key":"2019041604203870700_b29-0750861","article-title":"October 20, 2017 approval letter\u2014Shingrix","author":"Food and Drug Administration"},{"key":"2019041604203870700_b30-0750861","article-title":"CDC\u2019s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up","author":"GlaxoSmithKline","year":"2017"},{"key":"2019041604203870700_b31-0750861","article-title":"Comparison of a live herpes zoster vaccine and a recombinant vaccine in 50\u201359 and 70\u201385 year olds","author":"ClinicalTrials.gov"},{"key":"2019041604203870700_b32-0750861","article-title":"Study to evaluate efficacy, safety, and immunogenicity, of GlaxoSmithKline (GSK) Biologicals\u2019 herpes zoster vaccine GSK1437173A","author":"ClinicalTrials.gov"},{"key":"2019041604203870700_b33-0750861","article-title":"Immunogenicity and safety of GlaxoSmithKline (GSK) Biologics\u2019 herpes zoster subunit (HZ\/su) vaccine in adults 18 years of age or older with renal transplant","author":"ClinicalTrials.gov"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/75\/12\/861\/28450533\/ajhp0861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T04:29:08Z","timestamp":1555388948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/75\/12\/861\/5101956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp170399","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,15]]},"published":{"date-parts":[[2018,6,15]]}}}